# John Sheridan

> John Francis Sheridan is a San Diego-based American executive and the president and chief executive officer of Tandem Diabetes Care. He joined the company as executive vice president and chief operating officer in April 2013, became CEO in March 2019, and joined its board in June 2019. His previous leadership roles include Rapiscan Systems, Volcano Corporation, CardioNet and Digirad. He holds a chemistry degree from the University of West Florida and an MBA from Boston University.

- **Role:** President and Chief Executive Officer at Tandem Diabetes Care
- **Organizations:** Tandem Diabetes Care, Rapiscan Systems, Volcano Corporation, CardioNet, Digirad Corporation, Acutus Medical
- **Nationality:** American
- **Education:** B.S. in Chemistry, University of West Florida, MBA, Boston University
- **Known for:** Appointed Tandem President and CEO through an internal succession in March 2019., Joined Tandem’s board in June 2019., Tandem reported $1.015 billion in worldwide sales in 2025 during his tenure.

## Career timeline

- **1998-03 to 2002-05** — Vice President of Operations at Digirad Corporation.
- **2002-05 to 2004-05** — Executive Vice President of Operations at CardioNet.
- **2004-11 to 2010-03** — Executive Vice President of Research and Development and Operations at Volcano Corporation.
- **2012-03 to 2013-02** — Chief Operating Officer at Rapiscan Systems.
- **2013-04** — Joined Tandem as Executive Vice President and Chief Operating Officer.
- **2019-03** — Became Tandem President and Chief Executive Officer, effective March 1.
- **2019-06** — Joined Tandem’s board of directors.
- **2021-03 to 2025-04** — Served on the board of Acutus Medical.
- **2025** — Led Tandem during its first year exceeding $1 billion in worldwide sales.

## Achievements

- Appointed Tandem President and CEO through an internal succession in March 2019.
- Joined Tandem’s board in June 2019.
- Tandem reported $1.015 billion in worldwide sales in 2025 during his tenure.
- Held senior operations roles across five companies before becoming Tandem CEO.

## Latest updates

- **2026-08** — Tandem reported Q2 2026 worldwide sales of $254.6 million, 57% gross margin and a $21.2 million net loss; Sheridan said its strategy was gaining traction.
- **2026-03** — Discussed sales productivity, commercial systems and international direct operations at the TD Cowen conference.
- **2026-02** — Announced 2025 worldwide sales of $1.015 billion.
- **2025-04** — Appeared on Bloomberg Intelligence’s Vanguards of Health Care podcast; his Acutus board tenure ended in April 2025.

## Links

- Website: https://investor.tandemdiabetes.com/management/john-sheridan
- LinkedIn: https://www.linkedin.com/in/john-sheridan-84302315

---

Profile page: https://yespress.io/john-sheridan
Published by YesPress — https://yespress.io
Last updated: 2026-10-23